Technology
Health
Biotechnology

Kazia Therapeutics

$3.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-4.98%) Today
-$0.19 (-4.98%) Today

Why Robinhood?

You can buy or sell KZIA and other stocks, options, ETFs, and crypto commission-free!

About

Kazia Therapeutics Ltd. engages in the pharmaceutical drug development. It involves in preclinical research confirms efficacy of cantrixil which induces cell death in chemoresistant ovarian cancer stem cells. Read More The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Employees
Headquarters
Sydney, New South Wales (NSW)
Founded
1994
Market Cap
23.55M
Price-Earnings Ratio
Dividend Yield
Average Volume
9.79K
High Today
$3.80
Low Today
$3.60
Open Price
$3.80
Volume
3.94K
52 Week High
$6.19
52 Week Low
$2.04

Collections

Technology
Health
Biotechnology
Therapy
Pharmaceutical
Cancer Prevention

News

Simply Wall StFeb 20

Is Kazia Therapeutics Limited’s (ASX:KZA) CEO Pay Fair?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! James Garner has been the CEO of Kazia Therapeutics Limited (ASX:KZA) since 2016. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll look at a snap shot of the business growth. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to...

11
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.